Hepion Pharmaceuticals Inc is dedicated to developing innovative therapeutics for liver disease. With a strong focus on liver fibrosis and hepatocellular carcinoma, the company's corporate philosophy revolves around improving patient outcomes and addressing unmet medical needs. Hepion Pharmaceuticals Inc aims to deliver effective, safe, and cost-efficient treatments, prioritizing patient well-being in every aspect of their operations. By harnessing advanced technologies and collaborative partnerships, the company strives for excellence in research and development. With a steadfast commitment to scientific integrity and quality, Hepion Pharmaceuticals Inc is at the forefront of advancing liver disease therapeutics.

Hepion Pharmaceuticals Inc is primarily present in the United States.

Hepion Pharmaceuticals Inc has achieved significant milestones in its journey. One notable accomplishment is the successful development of CRV431, a cyclophilin inhibitor that has demonstrated potential therapeutic benefits for various liver diseases. The company has also advanced its clinical program by initiating Phase 2a clinical trials to evaluate the safety and efficacy of CRV431 in treating Non-Alcoholic Steatohepatitis (NASH), a prevalent liver condition. Furthermore, Hepion Pharmaceuticals Inc has strengthened its intellectual property portfolio, securing additional patents to protect its innovative drug candidates. These milestones illustrate the company's dedication to addressing unmet needs in liver disease treatments.

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drugs for the treatment of liver disease. Founded in 2013, Hepion is dedicated to finding innovative solutions to combat liver-related ailments, including non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company's research is rooted in its proprietary drug development platform, consisting of proprietary mechanisms and liver-targeted drugs. With a strong emphasis on drug discovery and development, Hepion Pharmaceuticals Inc aims to address the unmet medical needs of patients suffering from liver diseases through the advancement of its pipeline.

Some of the main competitors of Hepion Pharmaceuticals Inc in the market include Gilead Sciences Inc, Intercept Pharmaceuticals Inc, and ChronTech Pharma AB.

Hepion Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Hepion Pharmaceuticals Inc revolves around the development and commercialization of innovative therapeutic solutions for liver diseases. Hepion Pharmaceuticals Inc focuses primarily on the discovery and development of drugs that target disorders such as non-alcoholic steatohepatitis (NASH) and liver fibrosis. By leveraging its expertise in hepatology and drug development, the company aims to provide novel treatment options for patients suffering from liver-related disorders. Hepion Pharmaceuticals Inc combines cutting-edge research, advanced technology, and strategic partnerships to deliver effective pharmaceutical products that address the unmet needs of patients with liver diseases.

Коефициентът на цена спрямо печалбата (КЦП) на Hepion Pharmaceuticals е -0,04.

Коефициентът на цена към оборот (KUV) на Hepion Pharmaceuticals е 0.

AlleAktien качественият резултат за Hepion Pharmaceuticals е 4/10.

Приходите не могат да бъдат изчислени в момента за Hepion Pharmaceuticals.

очаквана Hepion Pharmaceuticals печалба е -67,62 млн. USD.

Hepion Pharmaceuticals Inc. is an emerging biotechnology company based in Edison, New Jersey, USA. The company focuses on developing novel therapeutics for the treatment of liver diseases and related metabolic diseases. They have a business model based on the discovery, development, and commercialization of innovative drugs for patients affected by liver diseases such as NASH and liver fibrosis. They have a range of products in different stages of clinical development, including CRV431 for the treatment of NASH and liver fibrosis, ARO-HSD for the treatment of Type 2 diabetes, and NASH-Predict, a tool for predicting NASH diagnosis. They also conduct extensive research and development programs to discover new drug candidates. The company is financed by investors and aims to globally market its products and establish a network of partners and distribution channels. Hepion Pharmaceuticals aims to become a leading company in the treatment of liver diseases and related metabolic diseases. Overall, the company has a promising business model based on the development of innovative therapeutics, collaboration with experts, successful funding, and planned global expansion channels.

Hepion Pharmaceuticals разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Hepion Pharmaceuticals в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Hepion Pharmaceuticals е US4268971045.

WKN на Hepion Pharmaceuticals е A2PN6W.

Тикерът на Hepion Pharmaceuticals е HEPA.

През последните 12 месеца Hepion Pharmaceuticals изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Hepion Pharmaceuticals да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Hepion Pharmaceuticals в момента е .

Hepion Pharmaceuticals изплаща дивидент на тримесечие. Той се разпределя в месеците .

Hepion Pharmaceuticals платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Hepion Pharmaceuticals се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Hepion Pharmaceuticals на 2.10.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 2.10.2024 г..

Последното дивидентно плащане беше извършено на 2.10.2024 г..

През година 2023 Hepion Pharmaceuticals изплати 0 USD под формата на дивиденти.

Дивидентите от Hepion Pharmaceuticals се изплащат в USD.